已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial

赛马鲁肽 安慰剂 医学 酒精使用障碍 不利影响 内科学 临床终点 酒 随机对照试验 减肥 物理疗法 临床试验 兴奋剂 酒精依赖 剂量 外科 意向治疗分析 试用登记 肥胖 疾病严重程度
作者
Mette Kruse Klausen,Signe Keller Justesen,Julie Niemann Pedersen,Line Rasmussen,Andreas Jensen,Mathias Ebbesen Jensen,Ulla Knorr,M Bergmann,Jens Juul Holst,Bolette Hartmann,George F. Koob,Helene Benveniste,Nora D. Volkow,Claus Thorn Ekstrøm,Gitte M. Knudsen,Tina Vilsbøll,Anders Fink‐Jensen
出处
期刊:The Lancet [Elsevier BV]
卷期号:407 (10540): 1687-1698 被引量:72
标识
DOI:10.1016/s0140-6736(26)00305-3
摘要

BACKGROUND: Alcohol use disorder accounts for 5% of deaths worldwide annually, and there is an urgent need for new therapeutic interventions. Preclinical and initial human studies indicate that the GLP-1 receptor agonist semaglutide might reduce alcohol drinking. This study evaluated the efficacy of semaglutide once-weekly in treatment-seeking patients with alcohol use disorder and comorbid obesity. METHODS: In a 26-week, single-centre, randomised, double-blinded, placebo-controlled trial, treatment-seeking participants with moderate to severe alcohol use disorder and comorbid obesity were assigned (1:1) to receive once-weekly semaglutide (2·4 mg subcutaneously) or placebo (saline subcutaneously), in addition to standard cognitive behavioural therapy. The primary endpoint was a reduction in the number of heavy drinking days assessed after 26 weeks of intervention, analysed with an ANCOVA model. Analysis adhered to the intention-to-treat principle, and missing outcome data were addressed using multiple imputations. Safety was assessed in all treated patients. The trial is registered at ClinicalTrials.govNCT05895643, and is complete. FINDINGS: From June 10, 2023, to Feb 4, 2025, 108 participants (53 women and 55 men) were enrolled, with 54 participants in each of the semaglutide and placebo treatment groups, and all were included in the data analysis. Overall, 88 participants (81%) completed the full intervention. Semaglutide was associated with a reduction in heavy drinking days (-41·1 percentage points from baseline, 95% CI -48·7 to -33·5) compared with placebo (-26·4, -34·1 to -18·6; estimated treatment difference -13·7 percentage points, -22·0 to -5·4; p=0·0015), and had substantial effects on multiple secondary alcohol-related and somatic outcomes. Adverse events were transient, generally mild to moderate gastrointestinal effects, and occurred more frequently in the semaglutide group. INTERPRETATION: Semaglutide showed robust therapeutic effects in treatment-seeking participants with obesity and alcohol use disorder and this trial supports previous preclinical and clinical findings suggesting GLP-1 receptor agonists as a potential novel treatment target for alcohol use disorder. FUNDING: The Research Foundation, Mental Health Services (Capital Region of Denmark), the Novo Nordisk Foundation, the Novavi Foundation, the Hartmann Foundation, and the Augustinus Foundation.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
2秒前
panda发布了新的文献求助10
2秒前
结实初翠发布了新的文献求助10
2秒前
2秒前
4秒前
粗心的小鸽子完成签到,获得积分10
4秒前
4秒前
5秒前
zhangzhirui完成签到 ,获得积分10
5秒前
6秒前
6秒前
6秒前
6秒前
8秒前
zjh发布了新的文献求助10
9秒前
沉静的时光完成签到 ,获得积分10
10秒前
晚风发布了新的文献求助30
10秒前
nighty完成签到 ,获得积分10
11秒前
12秒前
li完成签到 ,获得积分10
12秒前
天仙狂醉发布了新的文献求助10
13秒前
lili完成签到,获得积分20
14秒前
14秒前
柒月完成签到 ,获得积分10
14秒前
15秒前
16秒前
qq发布了新的文献求助10
16秒前
NexusExplorer的应助被石永怡采纳,获得20
17秒前
18秒前
18秒前
巫剑发布了新的文献求助10
19秒前
19秒前
洁净醉波完成签到 ,获得积分10
20秒前
21秒前
wxy发布了新的文献求助10
21秒前
英勇羿发布了新的文献求助10
23秒前
23秒前
24秒前
辛辛完成签到 ,获得积分10
24秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184723
求助须知:如何正确求助?哪些是违规求助? 9573702
关于积分的说明 21832740
捐赠科研通 7782090
什么是DOI,文献DOI怎么找? 3434404
关于科研通互助平台的介绍 2558528
邀请新用户注册赠送积分活动 2481054